HLA-F Antibody (YA3943)

(Synonyms: HLAF; CDA12; HLA-5.4; HLA-CDA12)

HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.

For research use only. We do not sell to patients.
  • Host:

    Mouse

  • Isotype:

    IgG2b

  • Application:

    WB, FC, ELISA

  • Reactivity :

    Human, Mouse, Rat

  • Formulation:

    Supplied in PBS with 0.05% sodium azide

  • Conjugation:
    Non-conjugated

Applications

Application
WB Info
WB: Western Blot
FC Info
FC: Flow Cytometry
ELISA Info
ELISA: Enzyme Linked Immunosorbent Assay
Dilution Ratio 1:500-1:2000 1:200-1:400 1:10000

Product Details

Description

HLA-F Antibody (YA3943) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to HLA-F.

  • Host Mouse
  • Clonality Monoclonal
  • Species Reactivity
    Human, Mouse, Rat
  • Observed Molecular Weight
    Observed band size: 40-50 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 39 kDa
Immunogen

Purified recombinant fragment of human HLA-F (AA: 22-305) expressed in E. Coli.

Purification

affinity purified.

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG2b

Product Properties

  • Appearance

    Liquid

  • Formulation

    Supplied in PBS with 0.05% sodium azide

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Background

  • Function

    HLA-F is a Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors. Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production. Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions. May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses. May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity[1][2][3][4][5].

  • Subcellular Localization

    Cell membrane; Single-pass type I membrane protein; Early endosome membrane; Lysosome membrane

  • Expression


    Tissue_specificity:Expression in resting B cells (protein level) . Expression in secondary lymphoid organs rich in B cells and T cells (such as tonsils, spleen, and thymus) (PubMed:10605026, PubMed:11169396) . Expression in tonsillar endothelial cells (PubMed:11169396) . Expression on activated lymphocytes (including B cells, NK cells, CD4+ T cells, and memory T cells) (PubMed:20865824, PubMed:27455421) . Expression in spinal motor neurons (PubMed:26928464) .

    Induction:Up-regulated in CD4+ T cells upon stimulation via TCR and upon HIV-1 infection

  • Isoforms & Post-Translational Modification

    P30511 has 3 isomers: P30511-1: 39062 Da (predicted); P30511-2: 28588 Da (predicted); P30511-3: 50438 Da (predicted).
    N-glycosylated

  • Subunit

    Forms a heterotrimer with B2M and a self-peptide (PubMed:28636952). Binds a diverse number of peptides ranging from 7 to more than 30 amino acids (PubMed:28636952). Peptide-bound HLA-F-B2M interacts with LILRB1 and LILRB2 but not with KIR3DS1 or KIR3DL2; this interaction is direct (PubMed:11169396, PubMed:28636952). The OC form interacts with KIR3DS1, KIR2DS4 and KIR3DL2; this interaction is direct (PubMed:24018270, PubMed:27455421, PubMed:28636952). Interacts with TAP1-TAP2 complex and CALR; this interaction is required for appropriate folding and peptide loading (PubMed:10605026, PubMed:11169396). Interacts with the coat protein complex II and 14-3-3 proteins; these interactions likely control the anterograde ER-to-Golgi transport of HLA-F (PubMed:16709803). HLA-F-B2M complex interacts with the heavy chain of other MHC class I molecules including HLA-A and HLA-E; this interaction may regulate the intracellular trafficking and the stability of peptide-free MHC class I OCs (PubMed:20483783)

  • SwissProt ID

    P30511

  • Gene ID
  • Synonyms

    HLAF; CDA12; HLA-5.4; HLA-CDA12

HLA-F Antibody (YA3943) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00